AHRR基因cg05575921低甲基化标志吸烟行为、疾病与死亡风险
在丹麦普通人群Copenhagen City Heart Study的9234人中,检测白细胞DNA中AHRR cg05575921甲基化水平并随访至22年,发现低甲基化与现吸烟/既往吸烟、高吸烟量及CHRN3A基因型相关;最低 vs 最高甲基化五分位者的多因素校正HR为COPD急性加重4.58、肺癌4.87、全因死亡1.67。在2576名符合CT肺癌筛查的高危吸烟者中,最低与最高甲基化五分位6年肺癌累积发生率分别为3.7%和0.0%,而PLCOM2012预测风险相似。
要点
- AHRR cg05575921低甲基化与吸烟行为及CHRN3A基因型相关。
- 最低 vs 最高甲基化五分位者COPD急性加重HR 4.58、肺癌HR 4.87、全因死亡HR 1.67。
- 高危吸烟者中最低甲基化五分位6年肺癌累积发生率为3.7%,最高为0.0%。
核心结论
- AHRR cg05575921低甲基化作为吸烟行为标志物,可预测未来吸烟相关疾病与死亡风险。
研究设计与样本
- 基于丹麦普通人群Copenhagen City Heart Study,纳入9234人,检测白细胞DNA中AHRR cg05575921甲基化,随访至22年。
- 以rs1051730(CHRN3A)基因型评估吸烟量,并按PLCOM2012计算6年肺癌风险。
主要发现
- AHRR低甲基化与既往吸烟、现吸烟、高每日吸烟量、高累积吸烟量及戒烟后时间短相关(所有p值<7×10-31)。
- AHRR低甲基化与吸烟相关CHRN3A基因型相关(每T等位基因-0.48%,p=0.002)。
- 最低 vs 最高甲基化五分位的多因素校正HR:COPD急性加重4.58(95%CI 2.83–7.42),肺癌4.87(95%CI 2.31–10.3),全因死亡1.67(95%CI 1.48–1.88)。
- 在2576名符合CT肺癌筛查的高危吸烟者中,最低与最高甲基化五分位6年肺癌累积发生率分别为3.7%和0.0%(p=2×10-7),PLCOM2012预测6年风险相似(4.3%和4.4%,p=0.77)。
关键数值与推荐
- AHRR cg05575921每T等位基因甲基化差异为-0.48%(p=0.002)。
- 最低 vs 最高甲基化五分位COPD急性加重HR 4.58(95%CI 2.83–7.42)。
- 最低 vs 最高甲基化五分位肺癌HR 4.87(95%CI 2.31–10.3)。
- 最低 vs 最高甲基化五分位全因死亡HR 1.67(95%CI 1.48–1.88)。
- 高危吸烟者最低与最高甲基化五分位6年肺癌累积发生率3.7% vs 0.0%(p=2×10-7),PLCOM2012预测风险4.3% vs 4.4%(p=0.77)。
临床怎么用
- AHRR cg05575921甲基化可作为客观吸烟暴露标志物,辅助评估吸烟相关疾病与死亡风险。
- 在符合CT肺癌筛查的高危吸烟者中,低甲基化可能帮助识别6年肺癌风险更高者,但需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE AND OBJECTIVES: Self-reported smoking underestimates disease risk. Smoking affects DNA methylation, in particular the cg05575921 site in the aryl hydrocarbon receptor repressor (AHRR) gene. We tested the hypothesis that AHRR cg05575921 hypomethylation is associated with risk of smoking-related morbidity and mortality. METHODS: From the Copenhagen City Heart Study representing the Danish general population, we studied 9234 individuals. Using bisulphite treated leucocyte DNA, AHRR (cg05575921) methylation was measured. Rs1051730 (CHRN3A) genotype was used to evaluate smoking heaviness. Participants were followed for up to 22 years for exacerbations of COPD, event of lung cancer and all-cause mortality. Six-year lung cancer risk was calculated according to the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCOM2012). MEASUREMENTS AND MAIN RESULTS: AHRR (cg05575921) hypomethylation was associated with former and current smoking status, high daily and cumulative smoking, short time since smoking cessation (all p values <7×10-31), and the smoking-related CHRN3A genotype (-0.48% per T-allele, p=0.002). The multifactorially adjusted HRs for the lowest versus highest methylation quintiles were 4.58 (95% CI 2.83 to 7.42) for COPD exacerbations, 4.87 (2.31 to 10.3) for lung cancer and 1.67 (1.48 to 1.88) for all-cause mortality. Finally, among 2576 high-risk smokers eligible for lung cancer screening by CT, observed cumulative incidences of lung cancer after 6 years for individuals in the lowest and highest methylation quintiles were 3.7% and 0.0% (p=2×10-7), whereas predicted PLCOM2012 6-year risks were similar (4.3% and 4.4%, p=0.77). CONCLUSION: AHRR (cg05575921) hypomethylation, a marker of smoking behaviour, provides potentially clinical relevant predictions of future smoking-related morbidity and mortality.
引用
- Bojesen SE, Timpson N, Relton C, et al. AHRR (cg05575921) hypomethylation marks smoking behaviour, morbidity and mortality. Thorax. 2017. PMID: 28100713. doi:10.1136/thoraxjnl-2016-208789
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。